MX339484B - Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante. - Google Patents

Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante.

Info

Publication number
MX339484B
MX339484B MX2012003892A MX2012003892A MX339484B MX 339484 B MX339484 B MX 339484B MX 2012003892 A MX2012003892 A MX 2012003892A MX 2012003892 A MX2012003892 A MX 2012003892A MX 339484 B MX339484 B MX 339484B
Authority
MX
Mexico
Prior art keywords
agent
exacerbation
human knee
knee osteoarthritis
preventative
Prior art date
Application number
MX2012003892A
Other languages
English (en)
Other versions
MX2012003892A (es
Inventor
Tatsuhiko Kuroda
Toshinori Ishizuya
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of MX2012003892A publication Critical patent/MX2012003892A/es
Publication of MX339484B publication Critical patent/MX339484B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de PTH (1-34) humana, para preparar un medicamento, para prevenir y/o tratar y/o limitar la exacerbación de la osteoartritis de rodilla humana concomitante con osteoporosis, en donde el medicamento está indicado para suministrar desde 100 hasta 200 unidades de PTH(1-34)/semana.
MX2012003892A 2009-11-18 2010-11-05 Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante. MX339484B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26221409P 2009-11-18 2009-11-18
PCT/JP2010/069742 WO2011062073A1 (ja) 2009-11-18 2010-11-05 ヒト変形性膝関節症の予防剤および／または治療剤および／または増悪抑制剤

Publications (2)

Publication Number Publication Date
MX2012003892A MX2012003892A (es) 2012-05-08
MX339484B true MX339484B (es) 2016-05-27

Family

ID=44059554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003892A MX339484B (es) 2009-11-18 2010-11-05 Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante.

Country Status (14)

Country Link
US (2) US20110172154A1 (es)
EP (1) EP2502632B1 (es)
JP (1) JP5969763B2 (es)
KR (1) KR101686271B1 (es)
CN (1) CN102686236A (es)
AU (1) AU2010320272B2 (es)
BR (1) BR112012002391A2 (es)
CA (1) CA2770340C (es)
ES (1) ES2616004T3 (es)
IL (1) IL217722B (es)
MX (1) MX339484B (es)
NZ (1) NZ598856A (es)
RU (1) RU2569754C2 (es)
WO (1) WO2011062073A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635576A (zh) * 2015-07-07 2018-01-26 旭化成制药株式会社 特发性股骨头坏死症的发病预防和/或进展抑制剂
JP7010934B2 (ja) * 2016-06-10 2022-02-10 レギュラキス 変形性関節症の治療のためのペプチド
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56140924A (en) 1980-04-04 1981-11-04 Teijin Ltd Calcitonin pharmaceutical preparation
GB2092002B (en) 1981-01-14 1985-09-11 Toyo Jozo Kk Suppositories injectable solutions
CA1188987A (en) 1981-03-06 1985-06-18 Masataka Morishita Preparation having excellent absorption property
JPS60161924A (ja) 1984-02-01 1985-08-23 Fujisawa Pharmaceut Co Ltd 肺吸収用組成物
JPS63243033A (ja) 1987-03-31 1988-10-07 Toyo Jozo Co Ltd 経鼻投与組成物
JPS63316737A (ja) 1987-06-19 1988-12-26 Toyo Jozo Co Ltd 経鼻投与用医薬組成物
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JPH02111A (ja) 1987-08-03 1990-01-05 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド製剤
JPH01230530A (ja) 1987-11-21 1989-09-14 Toyo Jozo Co Ltd カルシトニン類経鼻投与用液剤組成物
JPH02104531A (ja) 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
JPH078806B2 (ja) 1990-08-16 1995-02-01 旭化成工業株式会社 カルシトニン類含有経鼻投与用乳剤
JPH07238033A (ja) 1993-10-27 1995-09-12 Chugai Pharmaceut Co Ltd 軟骨整復術治療促進剤
JP2006137768A (ja) 1993-10-27 2006-06-01 Chugai Pharmaceut Co Ltd 軟骨整復術治療促進剤
JP3901761B2 (ja) 1995-02-20 2007-04-04 幸夫 加藤 変形性関節症および炎症性関節疾患治療剤
US6787518B1 (en) * 1995-02-20 2004-09-07 Yukio Kato Therapeutics of osteoarthritis and inflammatory joint disease
TWI293563B (en) 2000-06-30 2008-02-21 Asubio Pharma Co Ltd Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
WO2004067021A1 (en) * 2003-01-24 2004-08-12 Gardella Thomas J Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges
JPWO2005102381A1 (ja) * 2004-04-26 2008-03-06 小野薬品工業株式会社 カテプシンｋ阻害薬およびｐｔｈ類を併用することを特徴とする骨密度増加剤
JP2006143603A (ja) * 2004-11-16 2006-06-08 Asahi Kasei Pharma Kk 骨疾患治療用医薬複合剤
US20090010940A1 (en) * 2005-09-06 2009-01-08 Paul Morley Parathyroid Hormone Analogues and Methods of Use
WO2010045229A2 (en) * 2008-10-13 2010-04-22 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
US8586533B2 (en) * 2008-12-16 2013-11-19 Kaohsiung Medical University Treatment of early-stage osteoarthritis
US8530420B2 (en) * 2008-12-16 2013-09-10 Kaohsiung Medical University Treatment of arthritis with parathyroid hormone
KR102424644B1 (ko) * 2009-09-09 2022-07-25 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제

Also Published As

Publication number Publication date
AU2010320272B2 (en) 2015-01-22
JPWO2011062073A1 (ja) 2013-04-04
CA2770340C (en) 2019-08-27
ES2616004T3 (es) 2017-06-09
EP2502632A1 (en) 2012-09-26
IL217722A0 (en) 2012-03-29
IL217722B (en) 2018-06-28
BR112012002391A2 (pt) 2016-06-07
NZ598856A (en) 2013-10-25
EP2502632A4 (en) 2013-04-03
MX2012003892A (es) 2012-05-08
CA2770340A1 (en) 2011-05-26
RU2569754C2 (ru) 2015-11-27
AU2010320272A1 (en) 2012-04-12
KR20120116901A (ko) 2012-10-23
EP2502632B1 (en) 2016-12-28
CN102686236A (zh) 2012-09-19
RU2012125066A (ru) 2013-12-27
WO2011062073A1 (ja) 2011-05-26
JP5969763B2 (ja) 2016-08-17
US20130012440A1 (en) 2013-01-10
KR101686271B1 (ko) 2016-12-13
US20110172154A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
UA106634C2 (uk) Тверда фармацевтична дозована форма
PH12016500606A1 (en) Insulin preparations containing methionine
NZ603319A (en) Diabetes therapy
GB2491775A (en) Pulsatile drug release
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
IN2014MN00933A (es)
NZ602510A (en) Treatment of lupus nephritis using laquinimod
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
MX335951B (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
EP3308785A3 (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
MY157238A (en) Fused imidazoles and compositionsn comprising them for the treatment of parasitic diseases, such as e.g. malaria
NZ598600A (en) Therapeutic agent for rhinitis
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
EP2572711A4 (en) ANTIMALARIAL MEDICINE THAT CONTAINS 5-AMINOLEVULINIC ACID OR A DERIVATIVE AS AN ACTIVE INGREDIENT
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
EP2168586A4 (en) ACTIVE AGENT, REMEDY, PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF PATIENTS WITH DENTAL SYNDROME
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX339484B (es) Agente preventivo y/o agente terapeutico y/o agente supresivo del agravamiento para la artritis humana deformante.
GB2446341A (en) Method and system for transdermal drug delivery
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
IN2014CN04222A (es)

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration